CHIEF INVESTIGATOR

Professor Chris Hovens, Royal Melbourne Hospital (Australian data)

COLLABORATING INSTITUTIONS

TYPE/ROLE

Princess Margaret Cancer CentreLEAD INSTITUTE
Earlham InstituteLEAD INSTITUTE
Brigham and Women's HospitalLEAD INSTITUTE
Cambridge Research InstituteLEAD INSTITUTE
Chirurgien des Hôpitaux chez Hopitaux UniversitairesLEAD INSTITUTE
Dana Farber Cancer InstituteLEAD INSTITUTE
Wellcome Trust Sanger InstituteLEAD INSTITUTE
EMBLLEAD INSTITUTE
HCA HealthcareLEAD INSTITUTE
Princess Margaret Cancer CentreLEAD INSTITUTE
Prostate Cancer Research CenterLEAD INSTITUTE
The Institute of Cancer ResearchLEAD INSTITUTE
University of East AngliaLEAD INSTITUTE
University of HamburgLEAD INSTITUTE
University of OxfordLEAD INSTITUTE

GRANT

International consortium

SHARE ON SOCIAL MEDIA

tweet linkedin email

Many groups around the world have generated Whole Genome DNA Sequence (WGS) data. To co-ordinate this work Professor Eeles held the first Pan Prostate Cancer workshop in London on 3 October 2014. The attending groups unanimously supported the idea that the accumulated data, should be collected and compared in a common format including common storage, re-analysis through a single pipeline, and investigation to achieve a variety of scientific goals. The data collected so far includes WGS and exomes from 1400 tumours and matching bloods, but this number is likely to expand considerably. The combined collection would include the following categories: (i) cancers from different ethnic groups: eg Caucasian, Asian, Black Caribbean; (ii) cancer from different stages of progression from normal, to organ confined disease, to metastases; (iii) early onset prostate cancer; (iv) prostate cancer from aggressive and indolent disease; and (v) prostate cancer patients managed by different treatments with information linked to detailed and ongoing clinical follow up data. Full details.

Melbourne Bioinformatics’ involvement:

Three sites have been chosen to act as mirror sites for data analysis that will store and analyse all of the sequence data generated by the projects. These sites will be in EMBL Heidelberg, Germany; Sanger Centre, Cambridge, UK; and, Melbourne, Australia.

It is early days for this project. As part of the Technical Working Group we have gathered DNA sequencing data and begun processing hundreds of whole genomes collected from Australian patients. These results will be pooled with analysis performed by our international partners, yielding a highly significant resource for cancer researchers worldwide.